ArticleDiscover oncology2025
Long-term survival outcomes and subtype variations between primary breast cancer and liver metastases in 542 patients with advanced breast cancer: insights from a real-world analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinicopathological discordance and survival outcomes in 154 breast cancer patients with pulmonary metastasis in a real-world setting.Discover oncology · 2026Article
- Single-cell transcriptomics identify mechanical-memory-associated cell states in metastatic HRBreast cancer research : BCR · 2026Article
- Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis.The breast journal · 2026Article
- Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment.Cancer reports (Hoboken, N.J.) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to examine the incidence of receptor expression and the changes in subtypes observed between the primary breast cancer lesion and liver metastasis, and to investigate the impact of treatment patterns for various liver metastasis subtypes on patients' survival outcomes.
methodsA retrospective analysis was conducted on patients with breast cancer liver metastases at Peking University Cancer Hospital between 2008 and 2024.
resultsA total of 542 cases of breast cancer with liver metastasis were analyzed, of which 453 cases (83.6%) included complete receptor status records. The overall discordance rate between receptor expression in primary lesion and liver metastasis across the three subtypes was 23.6% (95% CI: 19.7-27.5), with a Kappa value of 0.55. The discordance rates for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression were 21.0% (95% CI: 17.2-24.7), 38.6% (95% CI: 34.1-43.1), and 10.8% (95% CI: 7.9-13.7), respectively, with corresponding Kappa values of 0.49, 0.27, and 0.68. Based on the receptor status of the liver metastasis, 321 cases (59.2%) were classified as HR+/HER2- type, 131 cases (24.2%) as HER2 + type, and 90 cases (16.6%) as triple-negative type. Significant differences were noted in median overall survival (OS) for liver metastasis among the three subtypes, measuring 58.0, 70.0, and 26.0 months, respectively (P < 0.001).
conclusionHeterogeneity in expression of ER, PR, and HER2 is evident between primary breast cancer and liver metastatic foci. Prognostic outcomes differ markedly across various subtypes of liver metastases, with specific challenges observed in cases exhibiting ER-/PR+, low ER expression, and low HER2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.